Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.

Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW; Utrecht Rheumatoid Arthritis Cohort Study Group.

Ann Intern Med. 2012 Mar 6;156(5):329-39. doi: 10.7326/0003-4819-156-5-201203060-00004.


Misclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices that do not include joints of feet.

Bakker MF, Jacobs JW, Kruize AA, van der Veen MJ, van Booma-Frankfort C, Vreugdenhil SA, Bijlsma JW, Lafeber FP, Welsing PM.

Ann Rheum Dis. 2012 Jun;71(6):830-5. doi: 10.1136/annrheumdis-2011-146670. Epub 2011 Nov 29.


Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study.

Bakker MF, Jacobs JW, Welsing PM, Vreugdenhil SA, van Booma-Frankfort C, Linn-Rasker SP, Ton E, Lafeber FP, Bijlsma JW; Utrecht Arthritis Cohort Study Group.

Ann Rheum Dis. 2011 Jun;70(6):1099-103. doi: 10.1136/ard.2010.137943. Epub 2011 Mar 15.


Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy.

Verstappen SM, Hoes JN, Ter Borg EJ, Bijlsma JW, Blaauw AA, van Albada-Kuipers GA, van Booma-Frankfort C, Jacobs JW.

Ann Rheum Dis. 2006 Nov;65(11):1506-11. Epub 2006 May 5.


Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year.

Verstappen SM, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, Borg EJ, Hofman DM, van der Veen MJ; Utrecht Arthritis Cohort Study Group.

Arthritis Rheum. 2003 Jul;48(7):1797-807.


Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.

van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM, Brus HL, van Albada-Kuipers GA, Heurkens AH, ter Borg EJ, Haanen HC, van Booma-Frankfort C, Schenk Y, Bijlsma JW.

Ann Rheum Dis. 2000 Jun;59(6):468-77.


The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis.

van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig-Meyling FH, van Booma-Frankfort C, de Jong BA, van Venrooij WJ, Bijlsma JW.

Clin Exp Rheumatol. 1999 Nov-Dec;17(6):689-97.


The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, van Albada-Kuipers GA, ter Borg EJ, Brus HL, Dinant HJ, Kruize AA, Schenk Y.

Ann Intern Med. 1996 Apr 15;124(8):699-707.


Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW.

Ann Rheum Dis. 1996 Apr;55(4):218-23. Erratum in: Ann Rheum Dis 1996 Aug;55(8):563.

Supplemental Content

Loading ...
Support Center